- Home
- RNTX vs SCNX Comparison
RNTX vs SCNX Comparison
Compare RNTX & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- SCNX
- Stock Information
- Founded
- RNTX 2001
- SCNX 2010
- Country
- RNTX United States
- SCNX United States
- Employees
- RNTX N/A
- SCNX N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- RNTX Health Care
- SCNX Health Care
- Exchange
- RNTX Nasdaq
- SCNX Nasdaq
- Market Cap
- RNTX 26.5M
- SCNX 21.2M
- IPO Year
- RNTX N/A
- SCNX 2020
- Fundamental
- Price
- RNTX $1.34
- SCNX $0.98
- Analyst Decision
- RNTX Hold
- SCNX
- Analyst Count
- RNTX 1
- SCNX 0
- Target Price
- RNTX N/A
- SCNX N/A
- AVG Volume (30 Days)
- RNTX 65.2K
- SCNX 431.3K
- Earning Date
- RNTX 08-14-2025
- SCNX 08-12-2025
- Dividend Yield
- RNTX N/A
- SCNX N/A
- EPS Growth
- RNTX N/A
- SCNX N/A
- EPS
- RNTX N/A
- SCNX N/A
- Revenue
- RNTX N/A
- SCNX $128,202.00
- Revenue This Year
- RNTX N/A
- SCNX N/A
- Revenue Next Year
- RNTX N/A
- SCNX N/A
- P/E Ratio
- RNTX N/A
- SCNX N/A
- Revenue Growth
- RNTX N/A
- SCNX N/A
- 52 Week Low
- RNTX $1.04
- SCNX $0.69
- 52 Week High
- RNTX $4.40
- SCNX $9.55
- Technical
- Relative Strength Index (RSI)
- RNTX 49.84
- SCNX 29.35
- Support Level
- RNTX $1.06
- SCNX $0.81
- Resistance Level
- RNTX $1.21
- SCNX $1.10
- Average True Range (ATR)
- RNTX 0.10
- SCNX 0.14
- MACD
- RNTX 0.02
- SCNX -0.06
- Stochastic Oscillator
- RNTX 66.67
- SCNX 10.54
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.